Replies to post #239715 on NorthWest Biotherapeutics Inc (NWBO)

[sukus]

If you include the survival rate into your calculation, dcvax-l may deserve a lot more valuation than novocure $9B mcap.

Dcvax-l
5 yr survival: minimum 20% estimate

Novocure
5 year survival: advertised at 13% but not sure what the actual number is.